• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Dexamethasone"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 20

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: Pilot study of an effective subtoxic therapy 

      Karavasilis, V.; Briassoulis, E. Ch; Siarabi, O.; Pavlidis, Nicholas (2003)
      Taxane-based chemotherapy has shown activity but also toxicity when administered at standard doses in patients with hormone-resistant prostate cancer (HRPC). In this pilot study, we investigated biweekly low-dose docetaxel ...

    • Article  

      Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature 

      Pectasides, Dimitrios; Aravantinos, Gerasimos; Fountzilas, George; Kalofonos, H. P.; Efstathiou, E.; Karina, M.; Pavlidis, Nicholas; Farmakis, D.; Economopoulos, T.; Dimopoulos, M. A. (2005)
      Background: Brain metastases from epithelial ovarian cancer (EOC) are rare. A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative ...

    • Article  

      Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study 

      Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)
      We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...

    • Article  

      Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study 

      Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)
      Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

    • Article  

      Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) 

      Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)
      In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

    • Article  

      Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP 

      Doumas, Stergios; Sakkas, L.; Panayiotidis, P.; Wozniak, Greta; Vlychou, M.; Vassilopoulos, G. (2014)

    • Article  

      Late toxicity in survivors from adolescent cancers 

      Pentheroudakis, George; Pavlidis, Nicholas (2007)
      Nowadays three quarters of adolescents with cancer are cured but half of them experience a late toxic effect of antineoplastic therapy that interferes with their physical and psychosocial health. This review recapitulates ...

    • Article  

      Management of leptomeningeal malignancy 

      Pentheroudakis, George; Pavlidis, Nicholas (2005)
      Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane. Leukaemias and lymphomas, lung, breast cancer and melanoma are the primary tumours commonly associated with ...

    • Article  

      Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group 

      Fountzilas, George; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, Anna; Maniadakis, N.; Aravantinos, Gerasimos; Syrigos, K.; Bamias, A. T.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H. P.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Pavlidis, Nicholas; Daniilidis, J. (2006)
      Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...

    • Article  

      Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group 

      Fountzilas, George; Athanasiades, A.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Briassoulis, E. Ch; Dombros, N.; Loannidis, I.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1997)
      37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There ...

    • Article  

      Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study 

      Aravantinos, Gerasimos; Fountzilas, George; Kosmidis, Paraskevas A.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, Dimosthenis V. (2005)
      Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin ...

    • Article  

      Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer 

      Bamias, A. T.; Papamichael, D.; Syrigos, K.; Pavlidis, Nicholas (2003)
      The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/ mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty ...

    • Article  

      Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group 

      Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Calvert, H.; Boddy, A. V.; Hollema, H.; Féty, R.; Vijgh, W. J. F. Van Der; Hempel, G.; Chatelut, E.; Karlsson, M.; Wilkins, J.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)
      Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time ...

    • Article  

      Prognostic factors in aggressive non-Hodgkin's lymphomas 

      Nikolaides, C.; Dimou, S.; Pavlidis, Nicholas (1998)
      Aggressive non-Hodgkin's lymphoma (NHL) is a biologically heterogeneous disease that can be cured with aggressive chemotherapy treatment. Different clinical, biological, cellular and molecular features have been identified ...

    • Article  

      Radiation and concurrent carboplatin administration in locally advanced head and neck cancer 

      Fountzilas, George; Skarlos, Dimosthenis V.; Nikolaou, A.; Kalogera-Fountzila, Anna; Tzitzikas, J.; Kosmidis, Paraskevas A.; Makrantonakis, P.; Samantas, E.; Karpasitis, N.; Bacoyiannis, Charalambos; Synodinou, M.; Pavlidis, Nicholas; Vritsios, A.; Daniilidis, J. (1995)
      Aims and Background: To improve local control in patients with locally advanced inoperable head and neck cancer we administered carboplatin concurrently with radiation. Methods: Thirty-nine patients entered the study. There ...

    • Article  

      A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group Study 

      Janinis, J.; Giannakakis, T.; Athanasiades, A.; Fountzilas, George; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Nikolaides, C.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (2000)
      Aims and background: The purpose of this multicenter randomized, open- label, parallel-group study was to assess whether the addition of low-dose dexamethasone to ondansetron results in improved control of chemotherapy- ...

    • Article  

      A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin 

      Pectasides, Dimitrios; Dafni, U.; Aravantinos, Gerasimos; Timotheadou, E.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Gaglia, A.; Kalofonos, H. P.; Fountzilas, George (2007)
      Objective: The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast ...

    • Article  

      Stress-induced impairment of macrophage tumoricidal function 

      Pavlidis, Nicholas; Chirigos, M. A. (1980)
      Several studies have shown the effect of stress on immune cells and their functions. The purpose of the present work was to investigate the influence of acute immobilization stress on macrophage nonspecific tumoricidal ...

    • Article  

      Trabectedin-related rhabdomyolysis: An uncommon but fatal toxicity 

      Stoyianni, A.; Kapodistrias, N.; Kampletsas, E. O.; Pentheroudakis, George; Pavlidis, Nicholas (2011)
      Rhabdomyolysis is defined as the dissolution of striped muscle characterized by the leakage of intracellular muscle components into the circulation, which can ultimately lead to renal failure with a possible fatal outcome. ...

    • Article  

      Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors 

      Briassoulis, E. Ch; Pentheroudakis, George; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2004)
      Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD